607
Participants
Start Date
October 31, 2011
Primary Completion Date
March 31, 2013
Study Completion Date
March 31, 2013
TAK-438
"In the treatment period, the participants will receive treatment of TAK-438 20 mg, tablets, orally, once daily for up to 8 weeks.~In the maintenance treatment period, the participants will receive treatment of TAK-438 10 mg, tablets, orally, once daily and lansoprazole placebo-matching capsules, orally, once daily for up to 24 weeks."
TAK-438
"In the treatment period, the participants will receive treatment of TAK-438 20 mg, tablets, orally, once daily for up to 8 weeks.~In the maintenance treatment period, the participants will receive treatment of TAK-438 20 mg, tablets, orally, once daily and lansoprazole placebo-matching capsules, orally, once daily for up to 24 weeks."
Lansoprazole
"In the treatment period, the participants will receive treatment of TAK-438 20 mg, tablets, orally, once daily for up to 8 weeks.~In the maintenance treatment period, the participants will receive treatment of TAK-438 placebo-matching tablets, orally, once daily and lansoprazole 15 mg, capsules, orally, once daily for up to 24 weeks."
Kashiwa-shi
Yachiyo-shi
Saijo-shi
Fukuoka
Kasuya-gun
Koriyama-shi
Takayama-shi
Annaka-shi
Asahikawa-shi
Sapporo
Itami-shi
Kobe
Nishinomiya-shi
Fujisawa-shi
Yokohama
Kochi
Kumamoto
Kyoto
Sendai
Nagasaki
Kishiwada-shi
Osaka
Suita-shi
Takatsuki-shi
Saga
Kumagaya-shi
Saitama-shi
Tokorozawa-shi
Bunkyo-ku
Chuo-ku
Hachioji-shi
Kokubunji-shi
Shibuya-ku
Shinjuku-ku
Toshima-ku
Shimonoseki-shi
Tsuru-shi
Lead Sponsor
Takeda
INDUSTRY